NEW YORK (GenomeWeb News) – Merck Serono and Compugen jointly announced today the formation of a new biomarker discovery firm focused on prediction of drug-induced toxicity.
The new venture, called Neviah Genomics, will operate out of the Merck Serono Israel Bioincubator and will receive funding from Merck Serono Ventures. Tel Aviv, Israel-based Compugen will provide predictive discovery technologies to the venture and will receive an undisclosed equity stake in the company and rights to royalties from potential future sales. Further terms of the agreement were not disclosed.
The establishment of Neviah Genomics builds on an earlier collaboration between Merck Serono and Compugen to discover biomarker signatures for drug-induced toxicity.